Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net loss	$ (6,966)	$ (8,129)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	33	40
Amortization of operating lease right-of-use assets	269	287
Loss on sale of fixed assets	116
Non-cash portion of the loss on lease termination	(114)
Share-based compensation expense	138	110
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(526)	(851)
Prepaid clinical trial expenses	832	647
Accounts payable	(494)	259
Operating lease liability	(260)	(267)
Accrued expenses and other liabilities	(965)	(387)
Net cash used in operating activities	(7,937)	(8,291)
Cash flows from investing activities:
Purchases of property and equipment	(28)	(143)
Proceeds from the sale of property and equipment	95
Net cash used in investing activities	67	(143)
(Decrease) Increase in cash and cash equivalents and restricted cash	(7,870)	(8,434)
Cash, cash equivalents and restricted cash at beginning of period	16,501	19,181
Cash, cash equivalents and restricted cash at end of period	$ 8,631	10,747
Supplemental disclosure of cash flow information and non-cash investing and financing activities:
Property and equipment in accounts payable and accrued expenses		$ 52